Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50242-0079-86 50242-0079 Inavolisib Itovebi 9.0 mg/1 Chemotherapy Enzyme Inhibitor PI3K⍺ Oral Jan 6, 2025 In Use
00310-4715-11 00310-4715 IV Solution Stabilizer for Lumoxiti IV Solution Stabilizer for Lumoxiti 6.5 mg/mL Ancillary Therapy Excipient Intravenous Oct 24, 2018 In Use
60505-6414-01 60505-6414 Melphalan HCl IVRA 90.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous May 9, 2025 In Use
80978-0641-01 80978-0641 Melphalan IVRA 90.0 mg/mL Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous Mar 19, 2025 In Use
70020-1910-01 70020-1910 Ixabepilone Ixempra Chemotherapy Antitumor Antibiotic Epothilones Intravenous Oct 16, 2007 In Use
00015-1910-12 00015-1910 Ixabepilone Ixempra Chemotherapy Antitumor Antibiotic Epothilones Intravenous Oct 16, 2007 Oct 31, 2017 No Longer Used
70020-1911-01 70020-1911 Ixabepilone Ixempra Chemotherapy Antitumor Antibiotic Epothilones Intravenous Oct 16, 2007 In Use
00015-1911-13 00015-1911 Ixabepilone Ixempra Chemotherapy Antitumor Antibiotic Epothilones Intravenous Oct 16, 2007 Oct 31, 2017 No Longer Used
50881-0010-01 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov 16, 2011 In Use
50881-0025-60 50881-0025 Ruxolitinib Jakafi 25.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
50881-0005-60 50881-0005 Ruxolitinib Jakafi 5.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
50881-0010-60 50881-0010 Ruxolitinib Jakafi 10.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1 and JAK 2 (Janus Kinase Inhibitor) Oral Nov 16, 2011 In Use
50881-0015-60 50881-0015 Ruxolitinib Jakafi 15.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
50881-0020-60 50881-0020 Ruxolitinib Jakafi 20.0 mg/1 Chemotherapy Enzyme Inhibitor JAK 1/2 Oral Nov 16, 2011 In Use
00002-7026-99 00002-7026 Pirtobrutinib JAYPIRCA 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Feb 15, 2023 In Use
00002-7026-60 00002-7026 Pirtobrutinib JAYPIRCA 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Jan 27, 2023 In Use
00002-6902-30 00002-6902 Pirtobrutinib JAYPIRCA 50.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral Jan 27, 2023 In Use
69605-0103-03 69605-0103 Mitomycin JELMYTO Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Instillation May 1, 2020 In Use
72493-0103-03 72493-0103 Mitomycin JELMYTO Chemotherapy Antitumor Antibiotic Alkylating Agent/ Mitomycin Instillation May 1, 2020 In Use
00173-0898-03 00173-0898 dostarlimab Jemperli 50.0 mg/mL Immunotherapy Checkpoint Inhibitor PD-1 Intravenous Apr 22, 2021 In Use
00024-5824-11 00024-5824 Cabazitaxel Jevtana Chemotherapy Antimitotic Agent Taxane Intravenous Jun 17, 2010 In Use
83257-0009-11 83257-0009 Bevacizumab-nwgd JOBEVNE 25.0 mg/mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 10, 2025 In Use
83257-0010-11 83257-0010 Bevacizumab-nwgd JOBEVNE 25.0 mg/mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 10, 2025 In Use
81927-0204-01 81927-0204 Methotrexate JYLAMVO 2.0 mg/mL Chemotherapy Antimetabolite Folic Acid Analog Oral Dec 15, 2023 In Use
50242-0088-01 50242-0088 ADO-Trastuzumab Emtansine Kadcyla 20.0 mg/mL, 20.0 mg/mL Immunotherapy Drug Antibody Conjugate HER2 Intravenous Feb 22, 2013 In Use

Found 11564 results — Export these results